| 1 | Surveillance Imaging Strategies for Pituitary Adenomas: When, How Frequent, and When to Stop | 2.0 | 9 | Citations (PDF) |
| 2 | Associations of Kidney Tubular Biomarkers With Incident Macroalbuminuria and Sustained Low eGFR in DCCT/EDIC | 5.6 | 14 | Citations (PDF) |
| 3 | Medical therapy of pituitary adenomas 2024, , 1-9 | | 0 | Citations (PDF) |
| 4 | CKD Associates with Cognitive Decline in Middle-Aged and Older Adults with Long-Standing Type 1 Diabetes | 1.4 | 6 | Citations (PDF) |
| 5 | MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly | 3.1 | 21 | Citations (PDF) |
| 6 | Effects of metformin and intensive lifestyle interventions on the incidence of kidney disease in adults in the DPP/DPPOS | 1.8 | 5 | Citations (PDF) |
| 7 | Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022 | 1.0 | 68 | Citations (PDF) |
| 8 | Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes | 5.6 | 7 | Citations (PDF) |
| 9 | Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial | 12.4 | 50 | Citations (PDF) |
| 10 | Glucocorticoid receptor blockers | 2.0 | 27 | Citations (PDF) |
| 11 | Urinary Angiotensinogen in Patients With Type 1 Diabetes With Microalbuminuria: Gender Differences and Effect of Intensive Insulin Therapy | 2.0 | 2 | Citations (PDF) |
| 12 | Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? | 0.2 | 55 | Citations (PDF) |
| 13 | Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands | 2.8 | 38 | Citations (PDF) |
| 14 | Prolactin and Other Pituitary Disorders in Kidney Disease | 1.4 | 22 | Citations (PDF) |
| 15 | A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands | 0.2 | 5 | Citations (PDF) |
| 16 | Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly | 0.2 | 2 | Citations (PDF) |
| 17 | Consensus on diagnosis and management of Cushing's disease: a guideline update | 12.4 | 890 | Citations (PDF) |
| 18 | Growth hormone replacement in adults: Real-world data from two large studies in US and Europe | 1.0 | 13 | Citations (PDF) |
| 19 | An evaluation of recurrent hypoglycemia across Chicago, Illinois | 1.8 | 1 | Citations (PDF) |
| 20 | Multidisciplinary management of acromegaly: A consensus | 5.1 | 331 | Citations (PDF) |
| 21 | Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide | 3.1 | 90 | Citations (PDF) |
| 22 | Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes | 26.4 | 361 | Citations (PDF) |
| 23 | A Pituitary Society update to acromegaly management guidelines | 2.0 | 301 | Citations (PDF) |
| 24 | Rebuttals to “The Debate on Insulin vs. Non-insulin Use in the Hospital Setting—Continued Use of Insulin or Time to Revise the Guidelines?” | 4.1 | 0 | Citations (PDF) |
| 25 | Use of Insulin in the Inpatient Setting: Need for Continued Use | 4.1 | 3 | Citations (PDF) |
| 26 | Pituitary Tumors in Pregnancy | 2.3 | 59 | Citations (PDF) |
| 27 | Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial | 3.1 | 29 | Citations (PDF) |
| 28 | Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus | 1.1 | 11 | Citations (PDF) |
| 29 | Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes | 3.2 | 47 | Citations (PDF) |
| 30 | Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data | 5.6 | 47 | Citations (PDF) |
| 31 | Risk Factors for Kidney Disease in Type 1 Diabetes | 5.6 | 124 | Citations (PDF) |
| 32 | Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline | 3.1 | 498 | Citations (PDF) |
| 33 | OR22-4 Recurrent Hypoglycemia, Fragmentation of Care, and Mortality in Chicago | 0.2 | 0 | Citations (PDF) |
| 34 | OR14-4 Early Glomerular Hyperfiltration and Long Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience | 0.2 | 0 | Citations (PDF) |
| 35 | The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials | 3.1 | 114 | Citations (PDF) |
| 36 | Development of a Predictive Model for Hyperglycemia in Nondiabetic Recipients After Liver Transplantation | 1.3 | 1 | Citations (PDF) |
| 37 | Hyperglycemia in the Posttransplant Period: NODAT vs Posttransplant Diabetes Mellitus | 0.2 | 21 | Citations (PDF) |
| 38 | Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials | 12.4 | 88 | Citations (PDF) |
| 39 | Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease | 1.8 | 18 | Citations (PDF) |
| 40 | Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis | 1.8 | 5 | Citations (PDF) |
| 41 | Validation of data from electronic data warehouse in diabetic ketoacidosis: Caution is needed | 1.8 | 20 | Citations (PDF) |
| 42 | New Onset Diabetes After Transplant: Data from the Folic Acid for Vascular Outcome Reduction in Transplantation Trial | 1.4 | 1 | Citations (PDF) |
| 43 | Lessons From the Testosterone Trials | 15.4 | 268 | Citations (PDF) |
| 44 | Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study | 3.1 | 27 | Citations (PDF) |
| 45 | Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone | 14.4 | 360 | Citations (PDF) |
| 46 | Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment | 14.4 | 217 | Citations (PDF) |
| 47 | Association of Testosterone Levels With Anemia in Older Men | 7.7 | 232 | Citations (PDF) |
| 48 | Diagnosis and Treatment of Pituitary Adenomas | 14.4 | 982 | Citations (PDF) |
| 49 | Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study | 4.9 | 175 | Citations (PDF) |
| 50 | Management of nonfunctioning pituitary adenomas (NFAs): observation | 2.0 | 51 | Citations (PDF) |
| 51 | Excellence in the treatment of patients with pituitary tumors | 2.0 | 5 | Citations (PDF) |
| 52 | A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry | 2.0 | 12 | Citations (PDF) |
| 53 | Evaluation of Outcomes and Complications in Patients Who Experience Hypoglycemia After Cardiac Surgery | 2.0 | 12 | Citations (PDF) |
| 54 | Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels | 2.0 | 8 | Citations (PDF) |
| 55 | An Evaluation of Recurrent Diabetic Ketoacidosis, Fragmentation of Care, and Mortality Across Chicago, Illinois | 5.6 | 92 | Citations (PDF) |
| 56 | Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study | 3.2 | 113 | Citations (PDF) |
| 57 | Inpatient Hypoglycemic Events in a Comparative Effectiveness Trial for Glycemic Control in a High-Risk Population | 2.0 | 8 | Citations (PDF) |
| 58 | Diabetes Care After Transplant | 2.2 | 49 | Citations (PDF) |
| 59 | Effects of Testosterone Treatment in Older Men | 26.4 | 847 | Citations (PDF) |
| 60 | Recruitment and Screening for the Testosterone Trials | 2.4 | 29 | Citations (PDF) |
| 61 | Management of diabetes mellitus in patients with chronic kidney disease | 1.5 | 118 | Citations (PDF) |
| 62 | Current approaches to the pharmacological management of Cushing's disease | 2.0 | 15 | Citations (PDF) |
| 63 | Cross-Disciplinary Biomarkers Research | 3.2 | 32 | Citations (PDF) |
| 64 | Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease | 2.0 | 153 | Citations (PDF) |
| 65 | Letter to the Editor: Parathyroidectomy Halts the Deterioration of Renal Function in Primary Hyperparathyroidism | 3.1 | 2 | Citations (PDF) |
| 66 | Examination of Implementation of Intravenous and Subcutaneous Insulin Protocols and Glycemic Control in Heart Transplant Patients | 2.0 | 14 | Citations (PDF) |
| 67 | The Authors Reply: | 4.2 | 0 | Citations (PDF) |
| 68 | The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men | 1.3 | 112 | Citations (PDF) |
| 69 | Insulin Therapy for Type 2 Diabetes Mellitus | 14.4 | 139 | Citations (PDF) |
| 70 | Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes | 0.2 | 45 | Citations (PDF) |
| 71 | Acromegaly: An Endocrine Society Clinical Practice Guideline | 3.1 | 1,653 | Citations (PDF) |
| 72 | Diabetic Kidney Disease: A Report From an ADA Consensus Conference | 1.0 | 524 | Citations (PDF) |
| 73 | Diabetic Kidney Disease: A Report From an ADA Consensus Conference | 5.6 | 1,040 | Citations (PDF) |
| 74 | Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria | 0.2 | 91 | Citations (PDF) |
| 75 | Surgical treatment of prolactinomas: cons | 1.8 | 27 | Citations (PDF) |
| 76 | Hyperglycemia and Insulin Resistance in Cardiac Arrest Patients Treated With Moderate Hypothermia | 3.1 | 16 | Citations (PDF) |
| 77 | Contextualized analysis of a needs assessment using the Theoretical Domains Framework: a case example in endocrinology | 1.6 | 2 | Citations (PDF) |
| 78 | Comparison of Glycemic and Surgical Outcomes After Change in Glycemic Targets in Cardiac Surgery Patients | 5.6 | 21 | Citations (PDF) |
| 79 | Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga | 5.6 | 173 | Citations (PDF) |
| 80 | We stand upon the shoulders of giants! | 2.0 | 0 | Citations (PDF) |
| 81 | Intensive glycemic control after heart transplantation is safe and effective for diabetic and non‐diabetic patients | 1.0 | 21 | Citations (PDF) |
| 82 | A New Therapeutic Approach in the Medical Treatment of Cushing’S SYNDROME: GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE | 2.0 | 64 | Citations (PDF) |
| 83 | Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry | 2.0 | 48 | Citations (PDF) |
| 84 | Management of medically refractory prolactinoma | 1.9 | 150 | Citations (PDF) |
| 85 | A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency | 5.6 | 97 | Citations (PDF) |
| 86 | Transsphenoidal Surgery for Cushing Disease | 1.5 | 128 | Citations (PDF) |
| 87 | Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome | 3.1 | 474 | Citations (PDF) |
| 88 | Tumors invading the cavernous sinus that cause internal carotid artery compression are rarely pituitary adenomas | 2.0 | 22 | Citations (PDF) |
| 89 | Management of Incidentally Found Nonfunctional Pituitary Tumors | 1.2 | 30 | Citations (PDF) |
| 90 | Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes | 3.1 | 63 | Citations (PDF) |
| 91 | Management of Post-Transplant Diabetes | 4.1 | 22 | Citations (PDF) |
| 92 | Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes | 26.4 | 553 | Citations (PDF) |
| 93 | Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline | 3.1 | 565 | Citations (PDF) |
| 94 | Prolactinoma in pregnancy | 3.4 | 106 | Citations (PDF) |
| 95 | Glycemic Control by A Glucose Management Service and Infection Rates After Liver Transplantation | 2.0 | 40 | Citations (PDF) |
| 96 | Positive Prolactin Response to Bromocriptine in 2 Patients with Cabergoline-Resistant Prolactinomas | 2.0 | 26 | Citations (PDF) |
| 97 | Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline | 3.1 | 804 | Citations (PDF) |
| 98 | Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria<subtitle>An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort</subtitle><alt-title>Microalbuminuria Outcomes in Type 1 Diabetes</alt-title> | 8.1 | 332 | Citations (PDF) |
| 99 | Patient Guide to Growth Hormone Deficiency in Adults | 3.1 | 1 | Citations (PDF) |
| 100 | Posttransplant Hyperglycemia is Associated With Increased Risk of Liver Allograft Rejection | 1.4 | 91 | Citations (PDF) |
| 101 | High Prevalence and Diversity of Kidney Dysfunction in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The BARI 2D Baseline Data | 0.3 | 18 | Citations (PDF) |
| 102 | Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study | 5.6 | 281 | Citations (PDF) |
| 103 | Comparison of Urinary Albumin-Creatinine Ratio and Albumin Excretion Rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study | 3.2 | 55 | Citations (PDF) |
| 104 | National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events | 4.2 | 52 | Citations (PDF) |
| 105 | Diabetes, Cardiovascular Risk and Nephropathy | 0.7 | 28 | Citations (PDF) |
| 106 | A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease | 26.4 | 1,833 | Citations (PDF) |
| 107 | Is Lack of Recombinant Growth Hormone (GH)-Releasing Hormone in the United States a Setback or Time to Consider Glucagon Testing for Adult GH Deficiency? | 3.1 | 80 | Citations (PDF) |
| 108 | Pituitary incidentalomas | 3.4 | 154 | Citations (PDF) |
| 109 | Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly | 2.0 | 62 | Citations (PDF) |
| 110 | The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome | 2.0 | 9 | Citations (PDF) |
| 111 | Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus | 2.0 | 24 | Citations (PDF) |
| 112 | Drugs and prolactin | 2.0 | 159 | Citations (PDF) |
| 113 | Insulin resistance following cardiothoracic surgery in patients with and without a preoperative diagnosis of type 2 diabetes during treatment with intravenous insulin therapy for postoperative hyperglycemia | 1.8 | 13 | Citations (PDF) |
| 114 | Nonfunctioning Pituitary Tumors and Pituitary Incidentalomas | 2.3 | 175 | Citations (PDF) |
| 115 | The Cabergoline-Resistant Prolactinoma Patient: New Challenges | 3.1 | 43 | Citations (PDF) |
| 116 | Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus | 8.1 | 114 | Citations (PDF) |
| 117 | Management of Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease | 2.0 | 52 | Citations (PDF) |
| 118 | La diabetes y la terapia basada en la incretina | 3.1 | 0 | Citations (PDF) |
| 119 | Guías de la Pituitary Society para el diagnóstico y tratamiento de los prolactinomas | 1.0 | 2 | Citations (PDF) |
| 120 | One View of Hospitalization | 2.0 | 0 | Citations (PDF) |
| 121 | Diabetes and Incretin-based Therapy | 3.1 | 0 | Citations (PDF) |
| 122 | Pituitary Disorders During Pregnancy | 2.3 | 64 | Citations (PDF) |
| 123 | Conversion of Intravenous Insulin Infusions to Subcutaneously Administered Insulin Glargine in Patients With Hyperglycemia | 2.0 | 100 | Citations (PDF) |
| 124 | Inpatient Management of Hyperglycemia: The Northwestern Experience | 2.0 | 98 | Citations (PDF) |
| 125 | Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas | 1.5 | 794 | Citations (PDF) |
| 126 | Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline | 3.1 | 417 | Citations (PDF) |
| 127 | Advances in the Treatment of Prolactinomas | 15.4 | 770 | Citations (PDF) |
| 128 | Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease | 3.2 | 56 | Citations (PDF) |
| 129 | Prolactin-secreting tumors: what’s new? | 1.5 | 17 | Citations (PDF) |
| 130 | Diabetes Tipo 1 | 3.1 | 1 | Citations (PDF) |
| 131 | Type 1 Diabetes | 3.1 | 5 | Citations (PDF) |
| 132 | Pharmacologic Resistance in Prolactinoma Patients | 2.0 | 187 | Citations (PDF) |
| 133 | The Pituitary Mass: Diagnosis and Management | 5.1 | 24 | Citations (PDF) |
| 134 | The incidence of Sheehan’s syndrome after obstetric hemorrhage | 2.2 | 64 | Citations (PDF) |
| 135 | Medication-Induced Hyperprolactinemia | 1.9 | 246 | Citations (PDF) |
| 136 | Diabetes and Hypertension: Pathogenesis, Prevention and Treatment | 3.7 | 93 | Citations (PDF) |
| 137 | Cortisol levels and mortality in severe sepsis | 1.5 | 143 | Citations (PDF) |
| 138 | La diabetes tipo 2 y la prueba A1c | 3.1 | 0 | Citations (PDF) |
| 139 | Type 2 Diabetes and A1c | 3.1 | 0 | Citations (PDF) |
| 140 | Title is missing! | 2.0 | 93 | Citations (PDF) |
| 141 | Title is missing! | 2.0 | 11 | Citations (PDF) |
| 142 | Epigenetic and genetic analysis of p16 in dermal fibroblasts from type 1 diabetic patients with nephropathy | 4.2 | 5 | Citations (PDF) |
| 143 | Timing and special concerns regarding endocrine surgery during pregnancy | 2.3 | 61 | Citations (PDF) |
| 144 | Pituitary tumors and pregnancy | 1.0 | 89 | Citations (PDF) |
| 145 | The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma | 3.1 | 96 | Citations (PDF) |
| 146 | Diagnosis of GH Deficiency in Adults—How Good Do the Criteria Need to Be? | 3.1 | 24 | Citations (PDF) |
| 147 | The relationship between glucose control and the development and progression of diabetic nephropathy | 4.1 | 27 | Citations (PDF) |
| 148 | Title is missing! | 2.0 | 98 | Citations (PDF) |
| 149 | Diagnosis of GH Deficiency in Adults--How Good Do the Criteria Need to Be? | 3.1 | 13 | Citations (PDF) |
| 150 | Endocrine Problems in the Chronically Critically Ill Patient | 1.6 | 22 | Citations (PDF) |
| 151 | DISORDERS OF PROLACTIN SECRETION | 2.3 | 158 | Citations (PDF) |
| 152 | Rise in Albuminuria and Blood Pressure in Patients Who Progressed to Diabetic Nephropathy in the Diabetes Control and Complications Trial | 0.2 | 24 | Citations (PDF) |
| 153 | Corticotropin-Releasing Hormone-Producing Medullary Thyroid Carcinoma Causing Cushing's Syndrome: Clinical and Pathological Findings | 2.2 | 7 | Citations (PDF) |
| 154 | Growth Hormone Therapy for Hypopituitary Adults: Time for Re-appraisal | 8.0 | 21 | Citations (PDF) |
| 155 | 10.1016/b978-0-323-60974-6.00043-8 | 0.0 | 0 | Citations (PDF) |
| 156 | MEDICAL TREATMENT OF PROLACTINOMAS | 2.3 | 146 | Citations (PDF) |
| 157 | Pituitary diseases in pregnancy | 1.7 | 77 | Citations (PDF) |
| 158 | Postoperative Radiotherapy for Clinically Nonfunctioning Pituitary Adenomas 1998, 8, 71-78 | | 9 | Citations (PDF) |
| 159 | The Case for Initial Surgical Removal of Certain Prolactinomas | 3.1 | 134 | Citations (PDF) |
| 160 | PITUITARY INCIDENTALOMAS | 2.3 | 79 | Citations (PDF) |
| 161 | Management of Early Diabetic Nephropathy | 1.4 | 32 | Citations (PDF) |
| 162 | The Case for Initial Surgical Removal of Certain Prolactinomas | 3.1 | 57 | Citations (PDF) |
| 163 | Evaluation and Management of Pituitary Tumors During Pregnancy | 2.0 | 10 | Citations (PDF) |
| 164 | Cerebrovascular disorders in patients with diabetes mellitus | 1.8 | 118 | Citations (PDF) |
| 165 | Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. | 3.1 | 175 | Citations (PDF) |
| 166 | Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. | 3.1 | 219 | Citations (PDF) |
| 167 | Clinical review 65. Evaluation and treatment of the patient with a pituitary incidentaloma | 3.1 | 116 | Citations (PDF) |
| 168 | Pituitary Adenomas | 7.3 | 3 | Citations (PDF) |
| 169 | Baseline analysis of renal function in the Diabetes Control and Complications Trial | 4.2 | 65 | Citations (PDF) |
| 170 | New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. | 3.1 | 34 | Citations (PDF) |
| 171 | Incidental Pituitary Adenomas | 0.3 | 33 | Citations (PDF) |
| 172 | Endocrine Problems of Adolescent Pregnancy | 2.3 | 1 | Citations (PDF) |
| 173 | Effects of Calcium Channel Blockade withVerapamil on the Prolactin Responsesto TRH, L-Dopa, and Bromocriptine | 0.3 | 12 | Citations (PDF) |
| 174 | Octreotide Treatment of Acromegaly | 7.3 | 261 | Citations (PDF) |
| 175 | 10 Endocrine emergencies in pregnancy | 1.9 | 36 | Citations (PDF) |
| 176 | Pathologic Hyperprolactinemia | 2.3 | 120 | Citations (PDF) |
| 177 | Clinical Manifestations of Acromegaly | 2.3 | 197 | Citations (PDF) |
| 178 | Unaltered Drug Metabolizing Enzyme Systems in Type II Diabetes Mellitus Before and During Glyburide Therapy | 1.3 | 9 | Citations (PDF) |
| 179 | Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-acting Non-Ergot Dopamine Agonist CV 205-502 | 7.3 | 72 | Citations (PDF) |
| 180 | Inhibition of Follicle-Stimulating Hormone Secretion from Gonadotroph Adenomas by Repetitive Administration of a Gonadotropin-Releasing Hormone Antagonist* | 3.1 | 35 | Citations (PDF) |
| 181 | Endocrinology | 14.4 | 0 | Citations (PDF) |
| 182 | Effect of Angiotensin-Converting Enzyme Inhibition on Pituitary Hormone Responses to Insulin-Induced Hypoglycemia in Humans* | 3.1 | 13 | Citations (PDF) |
| 183 | Occurrence of Intercapillary Nodular Glomerulosclerosis in the Absence of Glucose Intolerance | 1.0 | 13 | Citations (PDF) |
| 184 | Management of Prolactinomas | 10.5 | 34 | Citations (PDF) |
| 185 | CV 205–502 Treatment of Hyperprolactinemia* | 3.1 | 65 | Citations (PDF) |
| 186 | Diabetes mellitus | 1.5 | 8 | Citations (PDF) |
| 187 | Comparison of Ease of Learning of Four Glucose Meters | 2.9 | 1 | Citations (PDF) |
| 188 | The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women | 2.2 | 2 | Citations (PDF) |
| 189 | Pharmacokinetic Studies of Highly Purified Human Prolactin in Normal Human Subjects* | 3.1 | 14 | Citations (PDF) |
| 190 | A new strategy for clinical decision making: Censors and neuroendocrinological diseases | 4.5 | 1 | Citations (PDF) |
| 191 | Delayed chiasmal decompression after transsphenoidal operation for a pituitary adenoma | 1.5 | 0 | Citations (PDF) |
| 192 | Delayed Chiasmal Decompression after Transsphenoidal Operation for a Pituitary Adenoma | 1.5 | 10 | Citations (PDF) |
| 193 | Effects of Growth Hormone-Releasing Factor on Growth Hormone Secretion in Acromegaly∗ | 3.1 | 63 | Citations (PDF) |
| 194 | Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study* | 3.1 | 441 | Citations (PDF) |
| 195 | Pregnancy and the Hyperprolactinemic Woman | 26.4 | 262 | Citations (PDF) |
| 196 | Case 5-1985 | 26.4 | 30 | Citations (PDF) |
| 197 | Vasoactive Intestinal Peptide Is a Physiological Mediator of Prolactin Release in the Rat* | 1.8 | 267 | Citations (PDF) |
| 198 | Hyperprolactinemia in Patients With Renal Insufficiency and Chronic Renal Failure Requiring Hemodialysis or Chronic Ambulatory Peritoneal Dialysis | 1.0 | 122 | Citations (PDF) |
| 199 | Reversible hyperthyrotropinemia, hyperthyroxinemia, and hyperprolactinemia due to adrenal insufficiency | 1.4 | 52 | Citations (PDF) |
| 200 | The Cold Thyroid Nodule: An Analysis of Diagnostic and Therapeutic Options* | 15.4 | 92 | Citations (PDF) |
| 201 | Long-term Follow-up of Transsphenoidal Selective Adenomectomy for Prolactinoma | 14.4 | 68 | Citations (PDF) |
| 202 | Cavernous sinus syndrome due to prolactinoma: Resolution with bromocriptine | 1.3 | 21 | Citations (PDF) |
| 203 | Neuroendocrine alterations in systemic disease | 2.6 | 23 | Citations (PDF) |
| 204 | Aging and the thyroid | 1.4 | 136 | Citations (PDF) |
| 205 | Case 25-1983 | 26.4 | 6 | Citations (PDF) |
| 206 | Agranulocytosis Associated with Antithyroid Drugs | 7.3 | 223 | Citations (PDF) |
| 207 | Endocrinology and Metabolism | 14.4 | 0 | Citations (PDF) |
| 208 | Surgical Cure of Prolactinoma Reverses Abnormal Prolactin Response to Carbidopa/L-Dopa* | 3.1 | 17 | Citations (PDF) |
| 209 | Hyperprolactinemic disorders | 2.3 | 22 | Citations (PDF) |
| 210 | Is prolactin secreted ectopically? | 1.4 | 35 | Citations (PDF) |
| 211 | Bromocriptine Therapy in Acromegaly: Use in Patients Resistant to Conventional Therapy and Effect on Serum Levels of Somatomedin C* | 3.1 | 53 | Citations (PDF) |
| 212 | Clinical Cardiology and Diabetes, vol 3, part 1: Clinical Manifestations, Medical Management; part 2: Surgical Management, Renal Disease, Special Problems | 14.4 | 0 | Citations (PDF) |
| 213 | Lack of Modulation of Pituitary Hormone Stress Response by Neural Pathways Involving Opiate Receptors* | 3.1 | 80 | Citations (PDF) |
| 214 | Galactorrhea, Oligo/Amenorrhea, and Hyperprolactinemia in Patients with Craniopharyngiomas* | 3.1 | 53 | Citations (PDF) |
| 215 | Altered thyroid hormone levels in bacterial sepsis: The role of nutritional adequacy | 8.9 | 47 | Citations (PDF) |
| 216 | The Value of Computed Tomography in Evaluating Patients with Prolactinomas | 6.7 | 33 | Citations (PDF) |
| 217 | Selective Transsphenoidal Adenomectomy in Women With Galactorrhea-Amenorrhea | 14.4 | 88 | Citations (PDF) |
| 218 | Eosinophilic granuloma mimicking a pituitary tumor | 1.5 | 2 | Citations (PDF) |
| 219 | Eosinophilic Granuloma Mimicking a Pituitary Tumor | 1.5 | 23 | Citations (PDF) |
| 220 | Pseudonursing: a case of galactorrhea | 5.1 | 10 | Citations (PDF) |
| 221 | Thyroid Supplements and Breast Cancer | 14.4 | 1 | Citations (PDF) |
| 222 | Hyperlipemia During Estrogen Therapy | 14.4 | 0 | Citations (PDF) |
| 223 | Massive Hyperlipemia During Estrogen Therapy | 14.4 | 66 | Citations (PDF) |
| 224 | Title is missing! 0 | | 1 | Citations (PDF) |
| 225 | Title is missing! 0 | | 1 | Citations (PDF) |
| 226 | Title is missing! 0 | | 1 | Citations (PDF) |
| 227 | Title is missing! 0 | | 1 | Citations (PDF) |
| 228 | Debate: Surgery as Initial Therapy for Microprolactinoma | 3.1 | 3 | Citations (PDF) |
